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Abstract 
Aims: The benefit an individual can expect from preventive therapy varies based on risk-factor burden, 
competing risks, and treatment duration. We developed and validated the LIFEtime-perspective 
CardioVascular Disease (LIFE-CVD) model for the estimation of individual-level 10-year and lifetime 
treatment-effects of cholesterol-lowering, blood-pressure lowering, antithrombotic therapy, and 
smoking cessation in apparently healthy people.  
Methods and Results: Model development was conducted in the Multi-Ethnic Study of Atherosclerosis 
(n=6,715) using clinical predictors. The model consists of two complementary Fine and Gray competing-
risk adjusted left-truncated subdistribution hazard functions: one for hard CVD-events, and one for non-
CVD mortality. Therapy-effects were estimated by combining the functions with hazard ratios from 
preventive therapy trials. External validation was performed in the Atherosclerosis Risk in Communities 
(n=9,250), Heinz Nixdorf Recall (n=4,177), and the European Prospective Investigation into Cancer and 
Nutrition – Netherlands (n=25,833) and Norfolk (n=23,548) studies. Calibration of the LIFE-CVD model 
was good and c-statistics were 0.67–0.76. The output enables the comparison of short-term vs. long-
term therapy-benefit. In two people aged 45 and 70 with otherwise identical risk-factors, the older 
patient has a greater 10-year absolute risk reduction (15.8% versus 1.6%) but a smaller gain in life-years 
free of CVD (3.9 versus 4.5 years) from the same therapy. The model was developed into an interactive 
online calculator available via www.U-Prevent.com. 
Conclusion: The model can accurately estimate individual-level prognosis and treatment-effects in terms 
of improved 10-year risk, lifetime risk, and life-expectancy free of CVD. The model is easily accessible 
and can be used to facilitate personalized-medicine and doctor-patient communication. 
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Introduction  
Cardiovascular disease (CVD) is a significant cause of worldwide morbidity and healthcare costs. While 
healthy lifestyles should be universally recommended, in people without cardiovascular disease, lipid-
lowering, blood-pressure lowering, and antithrombotic therapy are recommended only when the risk-
factor burden is high or a certain 10-year CVD-risk threshold has been reached. 1 2 The benefit an 
individual can expect from preventive therapy varies based on risk-factor burden, competing risks, and 
treatment duration. For example, a high pre-treatment risk and longer treatment duration confer a 
greater absolute risk reduction (ARR).  
Estimating 10-year CVD-risk is thus an important aspect of CVD-prevention and various risk-assessment 
models have been endorsed by national and international guidelines.1-5 Age is a major driver of 10-year 
risk, and consequentially, the use of such short-term risk may delay treatment in young individuals with 
a high lifetime-benefit until an age at which a 10-year risk threshold is crossed. Conversely, therapy may 
provide a large 10-year ARR in older individuals, but an advanced age and limited life-expectancy may 
restrict gain in healthy life-years from preventive therapy.6 7 In recent years, guidelines have begun 
endorsing the use of lifetime risk-assessment in conjunction with short-term estimations.1 2 Existing 
lifetime scores such as QRISK-lifetime8 and the Pooled Cohorts Equations9 provide estimations of 
lifetime risk and the potential benefits of risk-factor modification. However, certain obstacles for the 
implementation of these scores are present. Not accounting for competing-risks or older baseline data 
commonly leads to over-estimation. Moreover, lifetime risk is not estimated for all ages, and the 
international generalizability or the availability of the external algorithms is lacking.2 10 There is thus a 
need to develop an internationally validated competing-risk adjusted model with the ability to estimate 
both 10-year and lifetime therapy-benefit. Such a model should estimate the effects of starting, 
stopping, altering, or postponing specific pharmacotherapies and lifestyle strategies.  
The objective of the present study was to develop and internationally validate a competing-risk adjusted 
LIFEtime-perspective model for individualizing CardioVascular Disease prevention strategies in 
apparently healthy people (LIFE-CVD). The LIFE-CVD model aims to estimate the effect of cholesterol 
lowering, blood pressure lowering, aspirin therapy, and smoking cessation in terms of 10-year and 
lifetime CVD-risk, and life-years gained free of CVD in apparently healthy people. The model will be 
made available via an online, interactive calculator. 
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Methods  
Study populations 
The study was conducted using data from multiple North-American and European cohorts. The Multi-
Ethnic Study of Atherosclerosis (MESA) cohort commenced recruitment in 2000 and is an ethnically and 
geographically diverse American cohort.11 The Atherosclerosis Risk in Communities Study (ARIC) 
commenced approximately 10-years earlier than MESA, but was otherwise similar in recruitment 
strategy and design. Due the difference in commencement years, the fourth follow-up visit in ARIC 
(1996-1998) was used as the baseline for these analyses.12 The Heinz Nixdorf Recall (Risk factors, 
Evaluation of Coronary Calcium and Lifestyle) Study (HNR, 2000-2003) is a population-based cohort 
study from the Ruhr area of Germany.13 The European Prospective Investigation into Cancer-
Netherlands (EPIC-NL, 1993-1997) study is formed by the Dutch MORGEN-EPIC and the Prospect-EPIC 
cohorts.14 The European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk, 1993-1997) is a 
population-based cohort from Norfolk area of the United Kingdom.15 Participants <45 years, with a 
history of CVD, heart-failure, CKD-EPI eGFR <30 mL/min/1.73m2 (not available in EPIC-NL), and terminal 
malignancy at baseline (not available in HNR) were excluded. Cohort details are described in 
supplemental table 1. As the model aims to estimate both therapy initiation, cessation, and alteration, 
no exclusion of participants was made based on medication use. As the model aims to estimate 10-year 
and lifetime risk for people aged 45-80 years, people >80 years at baseline were not included in 
validation cohorts. The upper age of 80 years was set because predictions become unstable as the size 
of an age-group becomes limited in the development cohort.1 2 Patients aged >80 years at baseline were 
included in the development cohort to provide stable estimations between the 80th and 90th life-years.  
Clinically applicable predictors  
Predictors were pre-specified based on the literature and availability in clinical practice: gender, systolic 
blood-pressure (SBP, mmHg), non-high-density lipoprotein cholesterol (non-HDLc, mmol/L), body-mass 
index (BMI, kg/m2), smoking status (current, former, never), presence of diabetes mellitus (yes / no, 
according to the 2007 American Diabetes Association fasting criteria), positive history of premature 
(prior to age 60) MI in either parent.1 2 8 Missing data handling is described in supplemental methods 1.  
Outcomes  
CVD-events were defined as fatal or non-fatal myocardial infarction (MI) or stroke, resuscitated cardiac 
arrest, and CHD-death. The competing-risk outcome was death from any other (non-CVD) cause. Follow-
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up time was defined as years until any of the first CVD-events, death, or end of follow-up. Supplemental 
table 2 provides an overview of the outcome definitions and adjudication processes.  
Model development  
The model was developed in the MESA-cohort due to the wide range of baseline ages, relatively recent 
commencement in the year 2000, and a high degree of racial/ethnic diversity. The statistical methods 
have previously been described in detail.16 In brief, the model comprises of two complementary Fine 
and Gray competing-risk adjusted left-truncated subdistribution hazard functions: one for CVD-events 
(subdistribution hazard function A) and one for non-CVD mortality ( subdistribution hazard function B). 
Age was used as the time-scale (i.e. left truncation), meaning participants contributed from the age of 
cohort entry to the age at end of follow-up. Continuous predictors were winsorized at the 1st and 99th 
percentile and transformed if this improved model fit. An interaction between age and predictor was 
used if non-proportionality indicated that the strength of a predictor changes with age (i.e. Schoenfeld 
residual p<0.05). Transformations and non-proportional hazards are described in the supplemental 
methods 1.  
Individual estimation of prognosis  
Individual estimations are based on life-tables with one-year age intervals. Each life-year has an age-
specific 1-year baseline survival for both CVD-events and CVD-mortality (supplemental table 3). The 
baseline survival was combined with the clinical predictors to estimate the risk of having a CVD-event or 
non-CVD mortality for each life-year as shown in supplemental table 4. The cumulative survival for each 
life-year was subsequently estimated by multiplying the survival probability of that life-year (1 minus 
CVD risk minus non-CVD mortality risk) by the survival probability at the beginning of each life-year. The 
(cumulative) survival thus depends on the combination of CVD-risk and non-CVD risk. The process was 
repeated until age 90 years to provide estimations of 10-year risk in people with baseline age up to 80 
years. A complete, reproducible, patient example of a life table is provided in supplemental table 5. 
Lifetime risk was defined as the risk of having a CVD-event before the 90th life-year. The CVD-free life-
expectancy is defined as the median survival without a CVD-event or death, and is thus equivalent to the 
age at which the cumulative survival probability becomes smaller than 0.5.  
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Table 1: Baseline characteristics 
 
MESA  
(n=6,715)  
ARIC 
(n=9,250) 
HNR 
(n=4,177)  
EPIC-NL 
(n=25,833)  
EPIC- Norfolk  
(n=23,548)  
Age (years) 62 (53-70) 62 (58-67) 59 (52-65) 55 (51-60) 59 (52–67)  
Gender (male)  53% 42% 47% 17% 44%  
Race  
   
  
Caucasian  39% 78% 100% 96% 100% 
African American  28% 22% 0% 0% 0% 
Other 34% 0% 0% 4%  0% 
Parental History of Premature MI  15% 16%  22% 13% 7%  
Body-mass index (kg/m2) 28 (25-31) 28 (25-31) 27 (25-30) 26 (23-28) 26 (24-28) 
Non-HDL (mmol/L) 3.7 (3.1-4.2) 3.9 (3.3-4.5) 4.4 (3.8-5.1) 4.3 (3.6-5.0) 4.7 (3.9–5.5)  
Systolic blood-pressure (mmHg) 124 (111-140) 125 (114-138) 132 (118-145) 129 (117-141) 134 (123–147)  
Smoking Status  
   
  
Current  14% 14% 23% 27% 12%  
Former  37% 42% 33% 35% 42% 
Diabetes Mellitus  14% 15% 12% 3% 2% 
Legend: Data are presented as median (25
th
 percentile – 75
th
 percentile) or frequency ( %). Abbreviations MI = myocardial infarction; non-HDL = non high-
density lipoprotein cholesterol; EPIC-NL is assumed to be 96% Caucasian based on genetic analyses.
17
 HNR is assumed to be 100% Caucasian.  
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Model validation  
Internal validation was performed on a set of MESA participants drawn by bootstrapping from the 
dataset of individuals aged 45-80 years at baseline. The lifetime model is based on one-year life table 
intervals, and may thus require internal intercept recalibration. Hence, the expected versus observed 
ratio of CVD-events and non-CVD mortality in MESA was used to recalibrate the intercepts. External 
validation was then performed in ARIC, HNR, EPIC-NL, and EPIC-Norfolk. Agreement between expected-
and-observed 10-year risks was assessed using calibration plots for CVD-events, non-CVD mortality, and 
the combined risk of these two events (i.e. the LIFE-CVD model). Geographical differences in event rates 
were corrected for by recalibrating the intercept in the HNR-study, and using the same recalibration 
coefficients for the other European cohorts. No recalibration was performed in ARIC as this has the 
same geographic location as the MESA-cohort.   
Race sensitivity analyses  
Race/ethnicity was not selected as a predictor due to the heterogeneity of definitions between 
countries, and the complex and poorly generalizable mechanisms via which race may mediate 
cardiovascular risk.18  However, in order to investigate model accuracy for different race/ethnicities, a 
race-stratified validation of the developed LIFE-CVD model was performed for African Americans and 
Caucasians in MESA and ARIC. Additionally, to compare the effects of race/ethnicity in the separate 
cohorts, two exploratory models were developed (one derived in MESA, the other in ARIC) which 
included race (i.e. African American, Caucasian or other) as a predictor. The multivariable hazard ratios 
(HRs) for race in these two models were compared.  
Individual therapy-benefit  
Altering the patient-characteristics to reflect updated risk-factors provides an observational, rather than 
a causal assessment, of risk-factor changes.9 In order to estimate the causal effects of therapy, the 
developed subdistribution hazard functions were combined with HRs obtained from randomized clinical 
trials and meta-analyses for cholesterol-lowering, blood pressure lowering, antithrombotic therapy, (i.e. 
aspirin or equivalent therapy) and smoking.9 By using the HRs from meta-analyses which analyzed trials 
including people both receiving and not receiving preventive therapy at baseline,  the effect of starting, 
stopping, intensifying, postponing, or reducing therapy can be estimated. Details are provided in 
supplemental methods 2. Cause-specific 1-year on-treatment survival was calculated by inserting the HR 
of treatment into either the proportional hazard function (A), (B), or both, as shown in supplemental 
table 4. The 10-year and lifetime ARR is the difference between on- and off-treatment predicted CVD-
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risk after 10-years or until 90 years of age, respectively. The gain in life-years free of CVD is estimated as 
the difference between on- and off-treatment CVD-free life-expectancy. Three patient examples are 
provided to demonstrate use of the LIFE-CVD tool to predict therapy-effects.  
Results  
Study population 
Baseline characteristics of the 69,523 participants are shown in table 1. The 6,715 MESA participants 
used for the derivation of the LIFE-CVD model were ethnically diverse, with 39% self-reporting as 
Caucasian, 28% as African American, 22% as Hispanic, and 12% as Chinese American. In MESA, 621 CVD-
events and 795 non-CVD deaths occurred over a median follow-up duration of 13.0 years. 
Development of the LIFE-CVD model   
Subdistribution HRs for CVD-events (A) and non-CVD mortality (B) are shown in table 2. These HRs are 
prognostic in nature and should not be viewed causally. Age-specific baseline survival (supplemental 
table 3) and the completed algorithm for both subdistribution hazard functions (supplemental table 4) 
are provided to enable external use of the full model.  
Table 2: Multivariable hazard ratios (HR) used in the LIFE-CVD model.  
 
Subdistribution hazard 
function A (CVD-events) 
Subdistribution hazard 
function B (non-CVD mortality) 
Gender (Male)  1.62 (1.38-1.92) 0.98 (0.83-1.17) * 
Systolic blood-pressure (per 10 mmHg)  1.12 (1.08-1.17)* 1.03 (1.00-1.07) 
Non-HDL Cholesterol (mmol/L) 1.13 (1.03-1.24) 0.83 (0.64-1.07)§  
Body Mass Index (kg/m2) 1.01 (1.00-1.03) 0.98 (0.62-1.56) § 
Former Smoker  1.03 (0.86-1.23) 1.26 (1.07-1.47) 
Current Smoker  1.59 (1.25-2.02)* 2.04 (1.65-2.52) * 
Diabetes Mellitus  1.76 (1.42-2.20)* 1.30 (1.04-1.63)* 
Parental History of Premature MI  1.46 (1.19-1.79) 0.93 (0.76-1.14) 
* Age-dependent variables. HRs shown for the median age of 62 years. 
§ 
Transformed variable. HRs shown for the 
75% inter quartile range versus the 25% inter quartile range (non-HDL-c 4.24 mmol/L versus 3.08 mmol/L; BMI 31 
kg/m
2 
versus 25 kg/m
2 
)  
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Internal Validation  
Of the 6,715 participants used for derivation, the 6,526 individuals between 45-80 years at baseline 
were resampled with replacement. The median predicted 10-year CVD risk is depicted in supplemental 
table 6. In this validation-set, the predicted 10-year risk for both CVD-events, non-CVD mortality, and 
combined outcome of CVD-events and all-cause mortality (i.e. the LIFE-CVD model), showed good 
agreement with the 10-year observed risk over all quintiles (figure 1). C-statistics for discrimination of 
the predicted versus observed 10-year CVD-risk was 0.73 (95% CI 0.71-0.74), non-CVD mortality risk was 
0.76 (95% CI 0.75-0.78), and combined risk 0.74 (95% CI 0.73-0.75).  
External Validation  
The expected versus observed ratio in the HNR study was 1.17 for CVD-events and 0.85 for non-CVD 
mortality. These recalibration coefficients were subsequently used and validated in the EPIC-NL and 
EPIC-Norfolk cohorts.  The predicted and observed 10-year risk for the combined outcome of CVD-
events and all-cause mortality showed good agreement (figure 2). C-statistics for discrimination ranged 
from 0.68 - 0.76 for CVD-risk, from 0.67 - 0.74 for the non-CVD mortality risk, and from 0.69- 0.76 for 
combined risk (supplemental table 7). 
Race Sensitivity analyses  
Race-stratified analyses were performed on the 1,887 African Americans and 2,600 Caucasians in the 
MESA validation set and the 2,029 African Americans and 7,194 Caucasians in the ARIC study. Stratified 
calibration plots are provided in supplemental figure 1. C-statistics ranged from 0.69 to 0.76 for African 
Americans and from 0.67 to 0.77 for Caucasians (supplemental table 8). In the exploratory model 
derived in MESA, which included race as a predictor, the multivariate HR for African-American compared 
versus Caucasians was non-significant. When the model was derived in ARIC, HRs were significant, but of 
different direction than those derived in MESA (supplemental table 9).  
Individual estimation of prognosis  
The developed LIFE-CVD model can be accessed via www.U-Prevent.com. Patient characteristics, current 
and future treatment, and age of treatment initiation can be entered into the tool. Three patient-
examples are provided in figure 3, in which the effect of concurrently achieving a blood-pressure target 
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Figure 1: Internal calibration of predicted versus observed 10-year risk with 95% confidence intervals in the MESA-
validation cohort for A) cause-specific CVD-event risk, B) cause-specific non-CVD mortality risk, and C) CVD-event 
and non-CVD mortality risk combined (i.e. the LIFE-CVD model).  
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Figure 2: External calibration of predicted versed observed 10-year risk of CVD-event and non-CVD mortality risk 
combined (i.e. the LIFE-CVD model) with 95% confidence intervals in A) ARIC B) HNR and C) EPIC-NL and D) EPIC-
Norfolk studies  
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Figure 3: Individualized therapy- benefit from atorvastatin 40 mg and achieving an SBP of 130 mmHg in three non-
diabetic, former-smoking, European males with a BMI of 28 kg/m
2
. MI = Myocardial infarction 
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 Patient A Patient B Patient C 
Non-HDL (mmol/L) 5.0 5.0 3.0 
Parental History of MI No No Yes 
Current Prognosis 
10-year CVD risk (%)  15.4 1.4 1.4 
Lifetime CVD risk (%)  34.0 39.4 32.0 
CVD-free life-expectancy (years) 85.0 82.3 82.4 
Therapy-benefit 
10-year ARR (%)  11.3 1.0 0.6 
Lifetime ARR (%)  23.8 27.2 12.7 
Gain in CVD-free years  3.4 4.5 2.1 
 
of 130 mmHg and initiating daily atorvastatin 40mg are compared. The 70-year old patient A has the 
exact same risk-profile as the 45-year old patient B. Patient A however has a higher 10-year CVD risk 
(15.5% versus 1.4%), but a lower lifetime risk (34.0% versus 39.4%) and a higher life-expectancy (85.0 
versus 82.3 years). Patients B and C have the same age and 10-year risk.  Patient B has higher SBP and 
LDL-c levels and thus a greater gain in CVD-free life-expectancy from modifying these risk-factors. The 
same risk-modifying strategy modelled in the individual patient examples (i.e. starting atorvastatin 40 
mg and achieving an SBP-target of 130 mmHg) was applied to the MESA-validation population and is 
shown in figure 4. Ten-year ARR increased with increasing baseline risk, and remained relatively 
consistent over each age stratum. Lifetime ARR and gain in CVD-free life-expectancy also increased with 
increasing baseline risk, but decreased with baseline age.  
Discussion 
In this study of 69,523 individuals, we developed and validated the LIFE-CVD model for apparently 
healthy people without cardiovascular disease between 45-80 years of age. International validation 
demonstrated the predictive reliability of the model. Individualized effects cholesterol lowering, blood 
pressure lowering, aspirin therapy, and smoking cessation can be estimated in terms of 10-year ARR, 
lifetime ARR, and gain in CVD-free life-years using readily available clinical characteristics. Calibration 
and discrimination are comparable to existing primary prevention models such as the Pooled Cohort 
Equations.1 For researchers, the fully specified algorithm with completed examples are presented to 
enable external use.  The clinical tool can be accessed freely via www.U-Prevent.com.  
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Figure 4: Distribution of individual A) 10-year ARR% B) Lifetime ARR% and C) gain in life-expectancy estimated for 
the 6,526 individuals in the MESA validation-cohort for immediate initiation of atorvastatin 40 mg and achieving an 
SBP of 130 mmHg stratified by baseline 10-year risk and age. No change in smoking status or aspirin use was 
modelled.  
Although the atherosclerotic process can begin in early adulthood, the majority of CVD-events happen 
after middle-age.19 Therefore, most younger adults have a lower 10-year CVD risk, and most older adults 
have a higher 10-year risk, regardless of risk-factor burden. However, the lifetime benefit decreases with 
age and increases with increasing risk-factor burden. Early initiation of risk-modifying strategies 
therefore results in greater lifetime therapy-benefit.6 This is intuitively demonstrated by the greater 
lifetime gain from quitting smoking at age 30 compared to age 60.20 It is therefore not surprising that a 
benefit-based approach to other therapies would shift eligibility away from older individuals and 
towards younger individuals with a high risk-factor burden. Lifetime risks in the ACC-AHA-ASCVD risk-
estimator (based on the Pooled Cohort Equation) are based on cumulative risk of CVD over 30 years, and 
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the score does not provide estimations of CVD-free life-expectancy. Although 30-year risk provides a 
greater time-horizon than 10-years, the use of a fixed time-horizon makes it difficult to compare the 
therapy benefit between individuals of different ages. Accordingly, the risk-calculator for this score does 
not provide 30-year risk estimations for individuals over 59 years of age.     
Lifetime estimates may be easier for the patient to understand, and integrating these estimates into 
decision-tools may enhance the clinician-patient risk-discussion.21 The use in clinical practice could help 
patients and clinicians gain insight into the individual effects of prevention when considering starting 
therapy, but also when side-effects are being experienced and therapy cessation, or daily-dose lowering, 
is desired. Lifetime estimates can also help identify patients who would benefit from early therapy-
initiation. However, early initiation also means a longer treatment duration, and thus also greater costs. 
On a population-level, cost-effectiveness studies can determine what gain in CVD-free life-years will 
outweigh the increased costs and harms of early treatment.  
The strengths of this study include combining a competing-risk adjusted model with the best available 
evidence on risk-reduction from therapy. Not accounting for competing risks leads to an overestimation 
of pretreatment CVD-risk in young individuals over the long term, or in any individual where the risk of a 
competing event is high. Trials and meta-analyses provide a comprehensive group-level analysis for 
individuals both on- and off- medications. As reliable evidence become available in the future, new 
prevention strategies will be added to the LIFE-CVD model. The study further used data from ethnically 
and geographically diverse population-based cohorts, allowing for both geographic recalibration, and 
the subsequent validation of the recalibration coefficients.  The slight underestimation of risk was seen 
in the highest baseline risk quintile of the external validation (observed CVD-risk > 10%). However, this 
may be of reduced clinical relevance, as the estimated risk already exceeds treatment thresholds  (7.5%) 
above which pharmacotherapy is often indicated in people without prior CVD.10 22 Race can be poorly 
defined and have different cultural definitions and gene/environment interactions in separate regions;23 
a view point reflected in the HRs for race found in the exploratory models when derived in both MESA 
and ARIC. For these reasons the model was derived in a multi-ethnic cohort, and the risk-factors thought 
to mediate the biological effects of race were included. A third strength is the use of the contemporary 
MESA cohort to derive the model, which commenced in 2000. Models derived using older baseline data 
may provide clinically significant overestimations of CVD-risk in contemporary populations.24 25  
Certain limitations should be acknowledged. Validation is performed for 10-year risk, as it is not feasible 
to perform validation over the course of an individual’s lifetime. Lifetime models assume that baseline 
16 
 
risks for each life-year remain stable over time. Previous studies have however shown the validity of 
lifetime predictions for up to 17 years.16 Nevertheless, as the follow-up duration in the validation cohort 
increases, the LIFE-CVD model could be updated and validated over the long-term. Also, lifetime 
estimations assume that all risk-factors, except age, remain stable over time. In reality, a patient may 
have an increase in blood-pressure of the course of a few years, or may develop co-morbidities. 
Therefore, lifetime estimations should be performed at regular time-intervals, such as every 10-years. 
Another important assumption of lifetime therapy-benefit estimations is that patients will be fully 
adherent to the prescribed medication for their remaining lifetimes. However, therapy-adherence is a 
common problem, and the LIFE-CVD model could be used as communication aid to address the 
importance of adherence and the consequences of non-adherence.  
CVD-prevention guidelines state that lifetime may be useful as a communication tool and that 
competing non-CVD death causes makes providing lifetime CVD estimates for some groups 
problematic.1 2 Although a few scores such as the QRISK provide lifetime estimations8, there are no 
competing-risk adjusted lifetime models which have been developed for the primary prevention 
populations in Europe as a whole.2 Similarly, the PCE is lacks competing-risk adjustment and only 
provides long-term estimates for younger individuals. The competing-risk adjusted LIFE-CVD model 
therefore fills gap. For populations not used in the development or validation (i.e. eastern European or 
Asian populations), the LIFE-CVD model represents the best available model to estimate treatment-
effects. Further investigations may also involve specific validation and eventual recalibration of the 
model to these geographic locations. In the future, including characteristics such as the presence of a 
monogenetic dyslipidemias, might improve predictions for those with these relatively rare 
characteristics. However, the addition of new markers to a well-functioning prognostic model rarely 
provides meaningful prognostic value to the model as a whole.26  
In conclusion, the LIFE-CVD model can estimate therapy-benefit from CVD risk-modification in 
apparently healthy people. The developed individualized-treatment tool is freely available via www.U-
Prevent.com and estimates the individualized benefit from cholesterol- and blood pressure- lowering, 
antithrombotic therapy, and smoking cessation in terms of  10-year and lifetime absolute CVD-risk 
reduction, and gain in CVD-free life-expectancy. Use of the tool may increase insight into therapy-
benefit via the complementary use of 10-year and lifetime estimates and may facilitate individualized 
medicine and doctor-patient communication. 
 
17 
 
Acknowledgements 
The MESA study is supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-
HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-
95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by 
grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The authors thank the other 
investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list 
of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. The 
views expressed in this manuscript are those of the authors and do not necessarily represent the views 
of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. 
Department of Health and Human Services. The Atherosclerosis Risk in Communities study has been 
funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, 
National Institutes of Health, Department of Health and Human Services, under Contract nos. 
(HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, 
HHSN268201700004I).  The authors thank the staff and participants of the ARIC study for their 
important contributions.The EPIC-NL study is supported by the “Europe Against Cancer” program of the 
European commission; Dutch ministry of health, Welfare and Sports; Netherlands Organization for 
Research and Development; and World Cancer Research Fund. The EPIC-Norfolk study  was supported 
by the Medical Research Council, UK http://www.mrc.ac.uk/ (Ref: G9502233 and MR/N003284/1) and 
Cancer Research UK http://www.cancerresearchuk. org/ (CRUK, Ref: SP2024/0201 and 14136). The 
authors acknowledge and thank study participants, general practitioners and the EPIC Norfolk study 
team for their contribution to the work. The HNR study was funded by the Heinz Nixdorf Foundation 
[Chairman: Martin Nixdorf; Past Chairman: Dr jur. Gerhard Schmidt (deceased)]. This study is also 
supported by the German Ministry of Education and Science (BMBF), and the German Aero-space 
Center [Deutsches Zentrum für Luft- und Raumfahrt (DLR)], Bonn, Germany. The German Research 
Council Assessment supported the study (DFG project: ER 155/6-2) and funded the study of psychosocial 
factors and neighborhood level information (DFG project SI 236/8-1 and SI 236/9-1). The sponsor of the 
study transferred the monitoring of the study to the German Ministry of Education and Science, Bonn, 
using an international advisory board and quality control as well as event committee, but had no role 
concerning the study design, data collection, analysis, interpretation, or writing the report.  
 
18 
 
References 
1. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: 
a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation 2014;129(25 Suppl 2):S49-73. 
2. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical 
practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular 
Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited 
experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & 
Rehabilitation (EACPR). Eur Heart J 2016;37(29):2315-81. 
3. Board JBS. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease 
(JBS3). Heart 2014;100 Suppl 2:ii1-ii67. 
4. Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and 
secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356. 
5. Network SIG. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 
Edinburgh: Scottish Intercollegiate Guidelines Network, 2007. 
6. Ferket BS, van Kempen BJ, Heeringa J, et al. Personalized prediction of lifetime benefits with statin therapy for 
asymptomatic individuals: a modeling study. PLoS Med 2012;9(12):e1001361. 
7. Koller MT, Leening MJ, Wolbers M, et al. Development and validation of a coronary risk prediction model for 
older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study. Ann Intern Med 
2012;157(6):389-97. 
8. Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation, and evaluation of a new QRISK model to 
estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010;341:c6624. 
9. Lloyd-Jones DM, Huffman MD, Karmali KN, et al. Estimating Longitudinal Risks and Benefits From Cardiovascular 
Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: 
A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 
2017;69(12):1617-36. 
10. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular 
risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2935-59. 
11. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J 
Epidemiol 2002;156(9):871-81. 
12. ARIC Atherosclerosis risk in communities study protocol, Manual 1, General Description and Study 
Management: The National Heart, Lung, and Blood Institute of the National Institutes of Health 1987. 
13. Schmermund A, Mohlenkamp S, Stang A, et al. Assessment of clinically silent atherosclerotic disease and 
established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged 
subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium 
and Lifestyle. Am Heart J 2002;144(2):212-8. 
14. Beulens JW, Monninkhof EM, Verschuren WM, et al. Cohort profile: the EPIC-NL study. Int J Epidemiol 
2010;39(5):1170-8. 
15. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European 
Prospective Investigation of Cancer. Br J Cancer 1999;80 Suppl 1:95-103. 
16. Dorresteijn JA, Kaasenbrood L, Cook NR, et al. How to translate clinical trial results into gain in healthy life 
expectancy for individual patients. BMJ 2016;352:i1548. 
17. Ganesh SK, Tragante V, Guo W, et al. Loci influencing blood pressure identified using a cardiovascular gene-
centric array. Hum Mol Genet 2013;22(8):1663-78. 
18. Jones DW, Chambless LE, Folsom AR, et al. Risk factors for coronary heart disease in African Americans: the 
atherosclerosis risk in communities study, 1987-1997. Arch Intern Med 2002;162(22):2565-71. 
19. Berenson GS, Srinivasan SR, Hunter SM, et al. Risk factors in early life as predictors of adult heart disease: the 
Bogalusa Heart Study. Am J Med Sci 1989;298(3):141-51. 
20. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British 
doctors. BMJ 2004;328(7455):1519. 
19 
 
21. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular 
disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 
2015;65(13):1361-68. 
22. Grundy SM, Stone NJ, Bailey AL, et al. 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood 
Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. J Am Coll Cardiol 2018. 
23. Fumo MT, Teeger S, Lang RM, et al. Diurnal blood pressure variation and cardiac mass in American blacks and 
whites and South African blacks. Am J Hypertens 1992;5(3):111-6. 
24. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk 
factors and preventive therapies on the performance of the American Heart Association-American College of 
Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J 
2017;38(8):598-608. 
25. Cook NR, Ridker PM. Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An 
Update. Ann Intern Med 2016;165(11):786-94. 
26. Austin PC, Pencinca MJ, Steyerberg EW. Predictive accuracy of novel risk factors and markers: A simulation 
study of the sensitivity of different performance measures for the Cox proportional hazards regression model. 
Stat Methods Med Res 2017;26(3):1053-77. 
27. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of 
LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 
2010;376(9753):1670-81. 
28. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic 
heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326(7404):1423. 
29. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin 
monotherapy and identification of factors associated with treatment response: a pooled analysis of over 
21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223(2):251-61. 
30. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and 
death: a systematic review and meta-analysis. Lancet 2016;387(10022):957-67. 
31. Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of 
vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 
2009;373(9678):1849-60. 
32. Mons U, Muezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and 
mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of 
the CHANCES consortium. BMJ 2015;350:h1551. 
33. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-
analysis. Arch Intern Med 2012;172(11):837-44. 
 
20 
 
Supplemental Methods 1  
Missing data  
Missing data was imputed separately in each cohort using additive regression and predictive mean 
matching with optimal weighted probability based on non-missing patient characteristics (aregImpute-
algorithm in R, Hmisc package).The frequency of missing data in each cohort is described below.  
In MESA, the percent of imputed variables was as follows: 0.03% for SBP, 0.04% for total cholesterol, 
0.09% for HDL-cholesterol, 0.3% for smoking status, 0.40% for diabetes status, 3.3% for parent’s age at 
MI where applicable and 10.8% for parental history of MI. 
In ARIC the percent of imputed variables was as follows: systolic blood-pressure 0.02%, body-mass index 
(kg/m2) 0.11%, diabetes status 0.47%, smoking status 0.53%, parental history of MI 8.0% and age at 
parental history of MI where applicable 8.2%.  
In the HNR study, the percent of imputed variables was as follows: HDL cholesterol 0.02%, systolic 
blood-pressure 0.2%, smoking status 0.1%, body-mass index 0.4%, parental myocardial infarction 7.8%, 
and age at parent’s MI when applicable 6.2%.  
In the EPIC-NL, the percent of imputed variables was as follows: body-mass index 0.1%, systolic blood 
pressure 0.3%, smoking status 0.5%, diabetes 0.6%, total cholesterol 3.7%, HDL-cholesterol 5.1%, age at 
parent’s myocardial infarction (12.4%) and parental history of myocardial infarction (yes, no, or 
unknown, 34.2%). 
In EPIC-Norfolk, the percent of imputed variables was as follows: diabetes status 0.1%, parental history 
of MI 0.1%, age at parent’s MI when applicable 0.1%,  body-mass index (kg/m2) 0.2%, systolic blood-
pressure 0.3%,  smoking status 0.9%, total cholesterol 6.9%, HDL cholesterol 9.9%.   
Transformations and non-proportionality of predictors 
For the CVD-sub distribution hazard model, no transformation of linear predictors was required. Non-
proportionality was seen with systolic blood-pressure (chi-squared = 6.5, p=0.01), current smoking (chi-
squared = 30.0, p=4.9 x 10-8), and type 2 diabetes (chi-squared = 6.5, p=0.011). For the competing-risk 
non-CVD mortality model, logarithmic transformations of non-HDL cholesterol and quadratic 
transformation of BMI improved model fit. Non-proportionality was seen for gender (chi-squared 4.1, 
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p=0.04), current smoking (chi-squared 1.3, p=2.5 x10-4), and type 2 diabetes (chi-squared 1.5, p=1.4x10-
4). 
 
Supplemental Methods 2  
CVD-events were defined as fatal or non-fatal myocardial infarction (MI) or stroke, resuscitated cardiac 
arrest, and CHD-death and is modelled with the subdistribution hazard function A. The competing-risk 
outcome was death from any other (non-CVD) cause and is modelled with subdistribtion hazard B.  As 
such, the effect of medication is modelled on the respective outcome (as shown in supplemental table 
4), and not the separate components of a composite outcome.  
Lipid-lowering effect 
The prediction of therapy-effects for lipid-lowering medications depends on the estimated change in 
LDL-c compared to baseline due to the medication. A 1 mmol/L reduction in LDL-c corresponds to a CVD 
hazard ratio of 0.78, and the expected relative risk reduction is modelled with 0.78^(LDL-c reduction 
from baseline).27 In the interactive calculator, the user can switch between prescription therapies (i.e. 
between atorvastatin 40 mg and atorvastatin 80mg). The expected LDL-c -reduction from baseline for 
each dose and type of statin is calculated based on a meta-analysis of 164 statin trials.28 The expected 
LDL-c from ezetimibe was derived from a meta-analyses and assumed to be 23.5% .29 The resulting 
hazard ratio for the effect of LDL-reduction is inserted into cardiovascular events subdistribution hazards 
function (A). Thus, although LDL-c is not used as a clinical predictor in the model, it is necessary to input 
the LDL-value into the interactive calculator in order to obtain the CVD hazard ratio for the effect of LDL-
c reduction.  
 
Blood-pressure lowering effect 
The effect of SBP-reduction was modelled into cardiovascular events subdistribution hazards function 
(A). A 10 mmHg reduction in SBP corresponds to a CVD hazard ratio of 0.74 (95% CI 0.67-0.83).30 Thus, 
an individual relative risk reduction associated with achieving a treatment target is 0.74((baseline SBP  minus 
target SBP) /10). In the interactive calculator, the user can estimate the effect of achieving certain systolic 
blood-pressure targets, as the choice of specific pharmacotherapy for blood-pressure lowering depends 
on the co-morbidities of the patient and significant blood-pressure lowering may be achieved with 
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lifestyle modification.  The effect of blood-pressure lowering was truncated at 130 mmHg with any 
reduction under 130 assumed to give a hazard ratio of 1.0.  
Antithrombotic effect 
The effect of antithrombotic therapy (aspirin or equivalent) was modelled into cardiovascular events 
subdistribution  hazards model (A). The CVD hazard ratio associated with the effect of aspirin therapy is 
0.88 (95% CI 0.82 – 0.94) and derived from a meta-analysis of six primary prevention trials.31 We assume 
that aspirin cessation is estimated as the inverse (i.e. HR 1/0.88 = 1.13). Other anti-coagulation therapy 
such as DOAC are generally recommended in the primary prevention setting.  
 
Smoking effect  
The effect of smoking cessation was modelled into both cardiovascular events subdistribution hazards 
function (A) and non-cardiovascular mortality subdistribution hazards function (B) and are derived from 
a large systematic reviews and meta-analyses. The hazard ratio for the CVD-event function (A) was 
derived using the reported hazard ratios for acute coronary events: former- versus never smokers 1.18 
(1.06 – 1.32); current-versus never smoker 1.98 (95% CI 1.75 – 2.25).32 The HR for former versus current 
smokers was thus estimated to be 1.18 / 1.98 = 0.60. The hazard ratio for model (B) was derived using 
the reported hazard ratios for all-cause mortality: former- versus never smokers 1.34 (05% CI 1.28-1.40); 
current- versus never smokers 1.83 (95% CI, 1.65-2.03).33 The HR for former versus current smokers was 
estimated to be 1.34 / 1.83 = 0.73.  
Combined effects 
The relative risk reduction for the combination of treatment are obtained by multiplying the HR’s for 
each therapy being considered, and inserting the log of the combined HR into the linear predictor. This 
corresponds to the effects of combined medication independent of each other. This is done separately 
for CVD-events and non-CVD mortality as shown in supplemental table 4.  
Median and area under the survival curve (AUC) estimations:  
When the median on- or off-treatment life-expectancy is estimated to be >90 years, the median survival 
does not reach 0.5. In these situations, the estimated gain in CVD-free life-expectancy is defined as the 
difference in the sum of the CVD-free survival probabilities for each remaining life-year. Graphically, this 
is equal to the on-treatment area under the survival curve (AUC) minus of off-treatment AUC.  
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Supplemental table 1: Cohort details  
MESA11  Method of Recruitment: Probability sampling from four communities (Forsyth County, NC; 
Northern Manhattan and the Bronx, NY; Baltimore City and Baltimore County, MD; St. Paul, MN; 
Chicago and the village of Maywood, IL; and Los Angeles County, CA) proceeded according to the 
discretion of the Field center according to the characteristics of its community, past experience, 
available resources, and site-specific logistics. Inclusion proceeded via pre-defined sex and 
race/ethnicity proportions.  
 Enrollment period: 2000-2002  
 Cohort participation criteria: Subjects must be living within geographic boundaries of a field center, 
between 45-84 years of age, free of known (self-reported) clinical cardiovascular disease, active 
cancer treatment, pregnancy, any serious medical condition which would prevent long-term 
participation; weight >136 kg; cognitive inability as judged by the interviewer; living in a nursing 
home or on the waiting list for a nursing home; plans to leave the community within five years; 
language barrier; chest CT scan in the past year. 
 
ARIC12 Method of Recruitment: Probability sampling within four communities (Forsyth County, North 
Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland) was 
used to randomly select households. All individuals aged 45-64 years were asked to participate. 
Participants were re-examined every three years. 
 Enrollment period: Initial recruitment: 1987-1989. For this study, variables collected at the fourth 
follow-up visit were used (1996-98).  
 Cohort participation criteria: Willing and able to participate.  
 
HNR13  Method of Recruitment: Random samples of men and women aged 45-74 were drawn from 
mandatory residency lists of three cities in the Ruhr area of Northwestern Germany (Essen, 
Mülheim and Bochum). Participants were invited via letter, and a maximum of two reminder 
letters and phone calls were made to the initial non-responders.  
 Enrollment period: December 2000 – August 2003 
 Cohort participation criteria: All subjects without cardiovascular disease willing to participate, 
without any conditions precluding follow-up over 5 years, pregnancy, or severe psychiatric illness.  
 
EPIC-NL14  Method of Recruitment: The Monitoring Project on Chronic Risk Factors (MORGEN project) 
recruited a random sample of participants from the general Dutch population, and included those 
aged 20-65. Prospect-EPIC cohort is based on volunteers recruited among women participating in a 
regional breast cancer screening program for whom all women, aged 50-69 receive biannual 
invitations.  
 Enrollment period: 1993 – 1997 
 Cohort participation criteria: Willing and able to participate and allow for linkage with the national 
hospital registries and mortality registries.  
 
EPIC-
Norfolk15 
Method of Recruitment: Recruited men and women aged 39-79 from the county of Norfolk from 
the population-based sampling frame of people registered with 35 participating General Practices.  
 Enrollment period: 1993 – 1997 
 Participation criteria: Willing and able to participate in baseline health.  
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Legend: MESA = Multi-ethnic Study of Atherosclerosis; ARIC = Atherosclerosis Risk in Communities Study; HNR = 
Heinz Nixdorf Recall Study; EPIC-NL = European Prospective Investigation into Cancer and Nutrition-Netherlands; 
EPIC-Norfolk = European Prospective Investigation into Cancer and Nutrition-Netherlands.  
 
 
Supplemental table 2: Outcome evaluation and definition  
MESA11  Outcome evaluation: Trained personnel evaluate the outcome based on ICD-codes and 
hospital records  
Acute myocardial infarction: Abnormal cardiac biomarkers (2 times upper limits of normal) 
regardless of pain or ECG findings; evolving Q waves regardless of pain or biomarker 
findings; or a combination of chest pain, and ST-T evolution or new LBBB, and biomarker 
levels 1-2 times upper limits of normal. 
Resuscitated Cardiac Arrest: Successfully recovered from a resuscitated cardiac arrest 
through pulmonary resuscitation (including cardioversion) 
Stroke (not TIA): Focal neurologic deficit lasting 24 hours or until death, or if < 24 hours, 
there was a clinically relevant lesion on brain imaging. Patients with focal neurologic deficits 
secondary to brain trauma, tumor, infection, or other non-vascular cause were excluded. 
CHD Death: Documented MI within the previous 28 days, chest pain within the 72 hours 
before death, and required absence of a known non-atherosclerotic or non-cardiac cause of 
death. 
 End of follow-up: December 31st, 2014   
 
ARIC12  Outcome evaluation: Events are ascertained by trained personnel by a combination of 
reviewing hospital records, and query of the patients, physicians, and family members, and 
are subsequently adjudicated by a committee of physicians. 
Acute myocardial infarction: Definite hospitalized MI defined as either 1. evolving diagnostic 
ECG pattern, or 2. diagnostic ECG pattern and abnormal enzymes, or 3. cardiac pain and 
abnormal enzymes in combination with either evolving ST-T pattern or equivocal ECG 
pattern. Probable hospitalized MI is defined as absence for definite MI and 1. Cardiac pain 
and abnormal enzymes, or 2. Cardiac pain and equivocal enzymes and either and evolving 
ST-T pattern or diagnostic ECG pattern, or 3. Abnormal enzymes and evolving ST-T pattern.  
Resuscitated Cardiac Arrest: Cardiac arrest, cause unspecified (ICD-10 427.5) 
 Stroke: Potential strokes were identified using ICD 9 discharge codes 160-167 or with 
mention of stroke in hospital discharge or death records and were evaluated by trained 
personnel. Strokes thought to be caused by vasculitis, major trauma, malignant neoplasm, 
infection, or hematological abnormalities were not included.  
 CHD Death: Definite or probable fatal CHD defined as lack of sufficient evidence to diagnose 
definite fatal MI, no known non-atherosclerotic or non-cardiac death that was probably 
lethal, and the presence of either a history of chest pain within 72 hours of death or a 
history of chronic ischemic heart disease such as coronary insufficiency or angina pectoris 
 End of follow-up: December 31st, 2014   
 
HNR13  Outcome evaluation: Vital status in subjects not reached by yearly follow-up is extracted 
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from mandatory citizen registries. For all possible primary study endpoints, hospital and 
nursing home records including electrocardiograms, laboratory values, and pathology 
reports were collected. For deceased subjects, death certificates were collected and 
interviews with general practitioners, relatives and eyewitnesses were under taken if 
possible. Medical records were obtained in 100% of all reported endpoints. An external 
criteria and endpoint committee blinded for conventional risk factor status and CAC scores 
reviewed all available documents of possible primary endpoints and classified the endpoints 
thereafter. 
 Acute myocardial infarction: We considered a myocardial infarction event according to the 
WHO MONICA diagnostic categories derived from symptoms, signs of electrocardiography, 
and enzymes (levels of creatine kinase (CK-MB)) as well as troponin T or I, and necropsy as 
(1) non-fatal acute myocardial infarction and (2) coronary death, which occurred after the 
baseline examination.  
Resuscitated Cardiac Arrest: Physician or emergency physicians documented fatal or non-
fatal cardiac arrest with resuscitation. 
Stroke (not TIA): Rapidly developing focal neurologic symptoms lasting at least 24 hours or 
until death due to no other than vascular cause. 
CHD Death: Death related to coronary heart disease documented in hospital records and 
confirmed by the event committee unrelated to any time intervals. 
 End of follow-up: May 2017 
 
EPIC-NL14  Outcome evaluation: Cause of death was obtained from Statistics Netherlands. Morbidity 
data (hospital contact) were obtained by linkage to the national hospital discharge register 
(HDR) using a validated probabilistic method. All outcomes were coded according to the 
Ninth Revision of the International Classification of Diseases (ICD-9)  until 1996, after which 
the Tenth Revision of the International Statistical Classification of Diseases (ICD-10) was 
used for hospital discharge diagnoses.  
Acute myocardial infarction: Hospitalization or death due to I21-I22  
Cardiac arrest: Hospitalization or death due to I46  
Stroke: Hospitalization or death due to I60-I66  
CHD Death: Death due to ICD I21-I25, I50, I46, R96  
 End of follow-up: December 31st, 2010 
 
EPIC-
Norfolk15  
Outcome evaluation: Cause of death was obtained via linkage to the UK Office of National 
statistics and death certificated coded by trained personnel. Morbidity data (hospital 
contact) were identified using linkage with the East Norfolk Health Authority (ENCORE) 
database, which records all hospital contacts throughout England and Wales for Norfolk 
residents.  All outcomes were coded according to the Tenth Revision of the International 
Classification of Diseases (ICD-10).  
Acute myocardial infarction: Hospitalization or death due to I21-I22  
Resuscitated cardiac arrest: Hospitalization or death due to I46  
Stroke: Hospitalization or death due to I60-I69  
CHD Death: Death due to ICD I21-I25, I46, I50 
 End of follow-up: December 31st, 2013 
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Supplemental table 3: Age-specific baseline survival for CVD-events (A) and non-CVD 
mortality (B) 
Age 1-Year events (A) 1-Year survival (B)  Age 1-Year survival (A) 1-Year survival (B) 
45 1 1  68 0.999645771 0.970398098 
46 1 0.979380684  69 0.999663492 0.965410198 
47 0.999725398 0.985480904  70 0.999566041 0.956805621 
48 1 0.978988162  71 0.999513256 0.95465345 
49 1 1  72 0.999692656 0.955233741 
50 0.99987841 0.98607217  73 0.999702516 0.953443559 
51 0.999516952 0.988522333  74 0.999679667 0.969421315 
52 0.999591619 0.985415629  75 0.999647779 0.947674229 
53 0.999792279 0.979056609  76 0.999630632 0.939724478 
54 0.9998799 0.985072499  77 0.999686488 0.954401682 
55 0.99941209 0.98989693  78 0.999661579 0.930794801 
56 0.999571482 0.990764307  79 0.999598915 0.9475237 
57 0.999699809 0.985900751  80 0.999725086 0.944907534 
58 0.999682114 0.986623736  81 0.999769337 0.931903316 
59 0.999511434 0.98713859  82 0.999684311 0.918651265 
60 0.999322636 0.97987487  83 0.999603926 0.916640537 
61 0.999656409 0.973393148  84 0.999668146 0.882636308 
62 0.999481427 0.966878497  85 0.999583733 0.90274824 
63 0.99963019 0.985990456  86 0.999488751 0.896307118 
64 0.999465298 0.977289395  87 0.999585936 0.884407038 
65 0.99972681 0.964981886  88 0.999723251 0.91857471 
66 0.999772552 0.976599292  89 0.999513316 0.868249158 
67 0.999693501 0.967697361     
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Supplemental table 4: Equation parameters for estimation of cause-specific 1-year survival  
Cardiovascular events proportional hazards function (A) 
1-year risk = 1- (age-specific 1-year baseline survival¥) ^exp(linear predictor A) 
 
Linear Predictor A =  
 0.4847013518(if male)-0.0166499486 * SBP(mmHg) + 0.0004577939 * SBP(mmHg) * age +  
0.1234667275 * non-HDL(mmol/L) + 0.0115363192 * BMI (kg/m2) + 0.0277998921(if former  
smoker) + 2.1116151356 * (if current smoker) – 0.0265661110 * age(if current smoker) + 1.73203611
78(if diabetes mellitus) – 0.0187873243 * age(if diabetes mellitus) + 0.3787129210 (if positive  
parental history of premature MI) – log(1.21)– log(1.17)(if Western Europe or Other) + log(CVD-specif
ic hazard ratio of risk-modifying strategy) §  
Non-cardiovascular mortality proportional hazards function (B)  
1-year risk = 1- (age-specific 1 year baseline survival¥)^exp(linear predictor B)  
 
Linear Predictor B = 
 - 2.622119558(if male)+0.041989661 * age(if male) + 0.003298955 * SBP(mmHg) – 0.596734702 *  
log(non-HDL(mmol/L))-0.112139195 BMI (kg/m2) + 0.001953504 * BMI(kg/m2) * BMI(kg/m2) +  
0.228458365(if former smoker) – 0.790213483(if current smoker) + 0.024262826 * age(if current  
smoker) + 0.687610988(if diabetes mellitus)-0.006812761 * age(if diabetes mellitus) – 0.072315309(if 
positive parental history of premature MI) –log(0.98)– log(0.85)(if Western Europe or Other) + log(no
n-CVD mortality specific hazard ratio of risk-modifying strategy)§ 
¥ 
Age-specific baseline survival functions are depicted in supplemental table 2.  
§ 
Hazard ratio of risk-modifying strategy is explained in supplemental methods.  
SBP = systolic blood pressure; HDL = high-density lipoprotein cholesterol; BMI = Body mass index; CVD= 
cardiovascular disease; MI = myocardial infarctions 
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Supplemental table 5: Example of a life table  
Age Cumulative 
Survival 
CVD Risk (%) Non-CVD mortality 
risk (%) 
Attributable 
CVD-risk 
Sum attributable 
risk 
70 1.000000 1.53 1.20 1.53 1.53 
71 0.972664 1.85 1.31 1.80 3.33 
72 0.941904 1.26 1.35 1.19 4.52 
73 0.917303 1.31 1.47 1.20 5.72 
74 0.891815 1.52 1.00 1.35 7.07 
75 0.869370 1.79 1.80 1.56 8.63 
76 0.838166 2.02 2.16 1.69 10.33 
77 0.803100 1.85 1.70 1.48 11.81 
78 0.774635 2.14 2.71 1.66 13.47 
79 0.737078 2.72 2.13 2.01 15.48 
80 0.701320 2.02 2.33 1.41 16.89 
81 0.670840 1.82 3.01 1.22 18.11 
82 0.638402 2.67 3.77 1.71 19.82 
83 0.597302 3.59 4.02 2.14 21.96 
84 0.551825 3.24 5.96 1.79 23.75 
85 0.501053 4.35 5.12 2.18 25.93 
86 0.453623 5.71 5.69 2.59 28.52 
87 0.401910 4.99 6.63 2.01 30.53 
88 0.355205 3.62 4.82 1.28 31.81 
89 0.325224 6.73 8.22 2.19 34.00 
90 0.276593     
 
Legend: Lifetable for patient example A (figure 3), 70 year old non-diabetic, formerly smoking male with a BMI of 
28 kg/m
2
, a non-HDL-c of 5.0 mmol/L, a SBP of 160mmHg, and a negative parental history of premature MI. CVD-
risk(%) and non-CVD(mortality) are derived using the equations depicted in supplemental table 4. CVD-free life-
expectancy is the age at which the cumulative survival drops below 0.5. For The sum of the attributable risk at the 
end of each life-year is the risk associated with that time-frame. this individual, the 10-year risk of CVD-events is 
15.5%, the lifetime risk of CVD-events is 34.0 and the CVD-free life-expectancy is 85.0 years. Attributable risk = CVD 
risk / (Non-CVD mortality risk + CVD risk)*(cumulative survival at beginning of current life-year – cumulative 
survival at beginning of next life-year).   
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Supplemental table 6: Median predicted 10-year risk of CVD per age 
Age 
Median Predicted 10-Year 
CVD Risk Men (%) 
Median Predicted 10-Year 
CVD Risk Woman(%) 
45 1.31 0.81 
46 1.91 1.16 
47 2.49 1.49 
48 3.05 1.82 
49 3.57 2.12 
50 4.06 2.42 
51 4.52 2.70 
52 4.95 2.97 
53 5.36 3.23 
54 5.74 3.47 
55 6.08 3.70 
56 6.41 3.92 
57 6.71 4.12 
58 6.95 4.28 
59 7.11 4.40 
60 7.27 4.51 
61 7.48 4.69 
62 7.75 4.90 
63 8.04 5.11 
64 8.33 5.35 
65 8.64 5.62 
66 8.93 5.93 
67 9.22 6.25 
68 9.54 6.62 
69 9.92 7.03 
70 10.35 7.47 
71 10.80 7.95 
72 11.29 8.46 
73 11.82 9.01 
74 12.37 9.59 
75 12.97 10.21 
76 13.60 10.87 
77 14.26 11.56 
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78 14.96 12.28 
79 15.70 13.04 
80 16.47 13.84 
Legend: Predicted values for 10-year CVD risk in men (n=3,241) and women (n=3,474) based on the respective 
loess curves (locally weighted scatterplot smoothing) of predicted 10-year risk as a function of age in the validation 
cohort of the Multi -  Ethnic Study of Atherosclerosis 
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Supplemental table 7: Discrimination of the LIFE-CVD model  
 
Subdistribution Hazard  
Function A (CVD-events)  
Subdistribution  Hazard  
Function B  (Non-CVD) mortality 
Combined events  
(LIFE-CVD model)  
MESA (n = 6,526) 0.73 (0.71-0.75) 0.76 (0.75-0.78) 0.74 (0.73-0.75) 
ARIC (n = 9,250) 0.68 (0.66-0.69) 0.71 (0.70-0.72) 0.70 (0.69-0.71) 
HNR (n = 4,177) 0.71 (0.68-0.74) 0.72 (0.70-0.75) 0.72 (0.70-0.74) 
EPIC-NL (n = 25,833) 0.71 (0.70-0.72) 0.67 (0.66-0.68) 0.69 (0.68-0.70) 
EPIC-Norfolk (n=23,548) 0.76 (0.76-0.77) 0.74 (0.73-0.75) 0.76 (0.75-0.76) 
Legend: Discrimination of expected versus observed risk is given as C-statistic (95% confidence interval) for both internal (MESA) and external (ARIC, HNR, EPIC-
NL) validation of 10-year risk. MESA = Multi-ethnic Study of Atherosclerosis; ARIC = Atherosclerosis Risk in Communities Study; HNR = Heinz Nixdorf Recall 
Study; EPIC-NL = European Prospective Investigation into Cancer and Nutrition-Netherlands; EPIC-Norfolk = European Prospective Investigation into Cancer and 
Nutrition-Norfolk.  
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Supplemental table 8: Race-stratified discrimination of the LIFE-CVD model  
  Subdistribution Hazard  
Function A  
(CVD-events)  
Subdistribution  
Hazard Function B  
(Non-CVD) mortality 
Combined events  
(LIFE-CVD model)  
MESA    
Caucasian  
( n = 2,600)  
0.74 (0.71-0.77) 0.77 (0.74-0.79) 0.74 (0.72-0.76) 
African American  
(n = 1,887)  
0.69 (0.66-0.73) 0.76 (0.73-0.79) 0.73 (0.71-0.75) 
ARIC     
Caucasian  
( n = 7,194) 
0.67 (0.66-0.69) 0.71 (0.70-0.73) 0.70 (0.69-0.71) 
African American  
(n = 2,029) 
0.68 (0.65-0.70) 0.70 (0.68-0.73) 0.69 (0.68-0.72) 
Legend: Discrimination of expected versus observed risk is given as C-statistic (95% confidence interval) for both 
internal (MESA) and external (ARIC) validation of 10-year risk, stratified by race. MESA = Multi-Ethnic Study of 
Atherosclerosis; ARIC = Atherosclerosis Risk in Communities Study; HNR = Heinz Nixdorf Recall Study;  
 
Supplemental table 9: Multivariable hazard ratios African-American versus Caucasian 
 
Subdistribution hazard 
function A (CVD-events) 
 
Subdistribution hazard 
function B (non-CVD 
mortality) 
African-American (MESA)  0.90 (0.73-1.10) 1.03 (0.86-1.22)  
African-American (ARIC)  1.34 (1.18-1.52) 0.89 (0.78 – 1.01)* 
Legend: Multivariate hazard ratios for African-American compared to Caucasian (ref) for a model derived in the 
Multi-Ethnic Study of Atherosclerosis (MESA) and a model derived in the Atherosclerosis Risk in Communities 
Study (ARIC).  
*Age-dependent variables. Hazard ratios shown for the median age of 62 years.  
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Supplemental figure 1: Internal and external validation of the predicted versed observed 10-year risk of CVD-
events and non-CVD mortality combined in MESA (A-C) and ARIC (D-F) stratified by race (African-American) and 
Caucasian. Bars represent 95% confidence intervals of observed risk in each quintile. 
